Objectives-To determine whether there is an association between morphologic types of tubal ectopic pregnancy (EP), 0-hour human chorionic gonadotropin (hCG) levels, and subsequent management success.
T he diagnosis of ectopic pregnancy (EP) in modern practice is based on the positive visualization of an extrauterine mass on transvaginal ultrasonography (TVUS). 1, 2 At the first presentation, TVUS has sensitivity of 73.9% in detecting EP. 3 The overall sensitivity of TVUS in detecting EP in subsequent visits is 87% to 99% with overall specificity of 94% to 99%. 2 There are 4 distinct TVUS morphologic criteria used to classify women with an EP: (1) an inhomogeneous mass, or "blob" sign, adjacent to the ovary and moving separately from it; (2) a mass with a hyperechoic ring around the gestational sac, or "bagel" sign; (3) a gestational sac with an embryonic pole with or without a yolk sac with cardiac activity; and (4) a gestational sac with an embryonic pole with or without a yolk sac without cardiac activity. In recent years, there has been a noticeable increase in the number of EPs diagnosed morphologically with the blob sign rather than a gestational sac with an embryonic pole or yolk sac. [4] [5] [6] [7] The association between these different EP morphologic types and subsequent management success has been examined in several studies. Most emphasized the presence of embryonic cardiac activity is an indication for surgical management, 8 whereas others found the presence of a yolk sac to be highly associated with failure of nonsurgical management. 9 The size of the EP mass has also been evaluated. Some studies pointed out that the size of the EP was not important for determining the likely outcome of nonsurgical management 5, 10 ; however, this finding was in contrast to other studies, in which this factor was found to be a significant predictor of success for expectant management. 8, 11 Biochemical markers, namely, human chorionic gonadotropin (hCG), have been extensively studied, and various cutoff levels for serum hCG at presentation have been evaluated. [12] [13] [14] Kirk et al 5 found that the most important variable for predicting the likelihood of successful nonsurgical management was the pretreatment hCG ratio (hCG at 48 hours to hCG at 0 hours). The aim of this study was to revisit and reevaluate the relationship between the morphologic appearance of tubal EP using TVUS, biochemical markers, and the success of subsequent management.
Materials and Methods

Study Design
We conducted a prospective observational cohort study of women presenting with tubal EP. 
Setting
Participants
Women presented to the Early Pregnancy Assessment Unit for an early pregnancy scan to confirm dates and viability and locate the pregnancy. Women included in the study were those who had an adnexal mass visualized on TVUS and those who had agreed for their deidentified information to be entered into the database on registration with the clinic.
Variables
Age, parity, details of previous deliveries, presenting symptoms, smoking status, and indications for the scan were determined by the clinician at the first visit. Peripheral blood was taken to measure the levels of serum hCG (World Health Organization, Geneva, Switzerland; Third International Reference 75/537) using automated electrochemiluminescence immunoassays at 0 hours and 48 hours later. All hCG levels were included (no threshold level at 0 hours was used to select management).
Ultrasonography (US) using a 4-9-MHz transvaginal transducer (X8 or Accuvix V20 Prestige; Samsung Medison, Seoul, Korea) was used. The US scans were performed by clinical fellows with previous experience of at least 1000 TVUS examinations.
The diagnosis of an EP by US was based on one of the following grayscale morphologic appearances: an inhomogeneous mass, or blob sign, adjacent to the ovary and moving separately from it ( Figure 1A) ; a mass with a hyperechoic ring around the gestational sac, or bagel sign ( Figure 1B) ; a gestational sac with an embryonic pole with or without a yolk sac with cardiac activity (ie, a viable extrauterine pregnancy; Figure 1C) ; or a gestational sac with an embryonic pole with or without a yolk sac without cardiac activity (ie, a nonviable extrauterine pregnancy; Figure 1D ). 
Follow-up
Women received expectant, medical, or surgical management depending on their clinical state, the presence or absence of embryonic cardiac activity, the presence or absence of hemoperitoneum in the pouch of Douglas, and the hCG ratio defined as hCG at 48 hours to hCG at 0 hours. 6 Women underwent surgery if they were hemodynamically unstable or presented with severe lower abdominal pain with or without bleeding, or the finding of a live embryo substantial hemoperitoneum was noted on TVUS. Substantial hemoperitoneum on TVUS was assessed in a semiquantitative way according to the level of blood in the pelvis relative to the uterus on a midsagittal plane (Figure 2 ). If this level exceeded the uterine fundus, the woman was offered surgical management. 15 Women who were clinically stable and did not have substantial hemoperitoneum on TVUS were eligible for nonsurgical intervention. Depending on the hCG ratio, if the hCG ratio was greater than 1.0 (ie, the serum hCG levels were increasing at 48 hours), then these women were selected for a single-dose intramuscular methotrexate injection (50 mg/m 2 of body surface area). If the hCG ratio was less than 1.0 (ie, the serum hCG levels were decreasing at 48 hours), then these women were selected for expectant management with weekly measurements of serum hCG until levels fell below 5 IU/L.
Statistical Analyses
To test for differences in patient characteristics, US signs, and hCG levels between surgical versus nonsurgical groups, we used the Wilcoxon rank sum test for continuous variables and the Fisher exact test for categorical variables. For assessment of the mass size, inhomogeneous masses with at least 1 measurement were included. For those with multiple measurements, the largest dimension was used. The Wilcoxon rank sum test was used to test for a relationship between continuous variables (the size of the blob sign in millimeters and the hCG level at 0 hours) and the success of nonsurgical management overall and separately for methotrexate and expectant management groups.
The relationship between US (blob sign, bagel sign, and mass size) and biochemical markers (hCG at 0 hours) and the success of nonsurgical management was assessed by logistic regression and presented as an odds ratio and 95% confidence interval (CI). For this analysis, an inhomogeneous mass size and the hCG level at 0 hours were assessed as continuous variables and also with the use of cutoff points (>30 or 30 mm for mass size and 1500 IU/L for hCG level at 0 hours). These cutoff points were chosen on the basis of National Center for Health and Care Excellence guideline values for nonsurgical management. 16 Statistical analyses were performed with SPSS version 23 software (IBM Corporation, Armonk, NY). P < .05 was defined as statistically significant.
Results
A total of 7350 consecutive women attended the Early Pregnancy Assessment Unit during the study period. A total of 341 (4.63%) women had a diagnosis of EP. After exclusion of nontubal EP, 301 (4.2%) women were included in the final analysis. Eighty-three of 301 (27.5%) women with a diagnosis of tubal EP had expectant management; 67 of 301 (22.2%) were administered methotrexate; and 151 of 301 (50%) had surgical management. The success rates for management were 77%, 75%, and 100%, respectively.
In the expectant management group, 19 cases failed initial management. Four women who had plateauing hCG levels were subsequently administered methotrexate (after 2-3 weeks of observation). Their hCG levels normalized within the next 4 weeks. The other 15 women presented with abdominal pain with or without bleeding and had surgical management. Seventeen women in the methotrexate group failed initial management. All of these women had presented with increasing abdominal pain between days 7 and 14 and therefore had surgical management.
The mean maternal age was 29.4 years (range, 17-42 years), and the median gestational age at diagnosis of EP was 43 days (range, 11-86 days); these variables were not statistically different between the surgical and nonsurgical management groups. More multiparous women required surgery, which was significantly different from the nonsurgical group (medical and expectant): 65% versus 53% (P < .03; Table 1 ). Lower abdominal pain was the main symptom and indication for scanning in the surgical group (78%); other variables did not vary significantly.
The morphologic blob sign type was present in 60.1% of our study population, and it was equally distributed between the different treatment groups (Table 1) . Similarly, the bagel sign was present in 29.9% of our study population and equally distributed between the 3 treatment groups. Twenty-three (7.6%) of the study population had a gestational sac with an embryo noted on TVUS; 20 of 23 (87%) had surgical management, and of the other 3, 2 had successful methotrexate management, and 1 had failed expectant management and subsequently needed surgery (these 3 showed a nonviable embryo on the initial TVUS scan).
In women eligible for expectant treatment, the blob sign was present in 53 of 83 cases; 67% of these cases had successful management ( Table 2 ). The presence of the blob sign was not statistically significantly associated with treatment success (P 5 .21; Table 2 ). The sensitivity of the presence of the blob sign to correctly predict success was 68% (95% CI, 55%-79%). The bagel sign was present in 28 of 83 cases; 32% had successful management; and the sensitivity and specificity to predict success were 31.7% (95% CI, 20%-44%) and 57% (95% CI, 33%-79%), respectively.
In women eligible for medical treatment, the blob and bagel signs were present in 45 and 18 of 67, respectively. The sensitivity of the blob and bagel signs to correctly predict success were 71% (95% CI, 57%-83%) and 26% (95% CI, 14%-41%), respectively.
We further analyzed the relationship between the blob mass size and outcome (success or not) for each group. The overall mean size of the blob mass 6 SD (22.5 6 11.7 mm) was statistically different between the surgical and nonsurgical groups (P 5 .001). There was, however, no difference in the mean mass size between medical and expectant management groups (P 5 .10; Data are presented as number (percent), mean 6 SD, and median (range) where applicable. Data are presented as number (percent), mean 6 SD, and median (range) where applicable. OR indicates odds ratio.
Nadim et al-Ultrasonographic and Biochemical Markers of Tubal Ectopic Pregnancy
J Ultrasound Med 2018; 00:00-00 Table 1 ). Overall, the success of management in the expectant and medical groups was not correlated with the mean mass size (Table 2 ). In the expectant management group, of the 80 cases that had a mass size if less than 30 mm in diameter, 61 of 80 (95%) had a successful outcome, whereas all 3 cases with a mass size greater than 30 mm had a successful outcome (odds ratio, 0.76; 95% CI, 0.67-0.86). In the medical management group, 7 of 67 cases had a mass size of greater than 30 mm diameter; of these, only 2 failed medical management (odds ratio, 0.7; 95% CI, 0.1-4.1; Table 2 ). In the methotrexate treatment group, we found that the mean EP size was 3.4 mm greater in the failed treatment group than the treatment success group, suggesting a potential association between a larger EP size and risk of treatment failure. However, the variability in the EP size was large in this group (SD > 5 mm), and the sample size (17 treatment failures) was insufficient to provide 80% power to detect a statistically significant difference of this magnitude. Overall higher hCG levels at 0 hours were associated with management failure in each of the nonsurgical management groups. The median hCG level for failure was 589 IU/L versus 366 IU/L for success in the expectant management group, whereas the median hCG level for failure in the methotrexate-treated group was 1244 IU/L versus 629 IU/L (P 5 .01) for success ( Table 2) .
With a cutoff value for the serum hCG level at 0 hours of 1500 IU/L, 66 of 83 (80%) of the expectant management group had a serum hCG level below this cutoff. The success rates for expectant management at levels of serum hCG above and below 1500 IU/L were 75% and 78%, respectively (Table 2 ). In the methotrexatetreated group, 20 of 67 (30%) women had serum hCG levels above 1500 IU/L. The rates of success for the methotrexate-treated group at levels of serum hCG above and below 1500 IU/L were 72% and 80% (P 5 .45; Table 2) . Tables 3 and 4 show the areas under the receiver operating characteristic curves for the blob sign, bagel sign, adnexal mass size, hCG serum levels at 0 and 48 hours, hCG ratio, presence of hemoperitoneum, vaginal bleeding, and lower abdominal pain to detect the success rate for each of the nonsurgical management groups. Figure 3 illustrates the receiver operating characteristic curves for the medical management group ( Figure 3A ) and expectant management group ( Figure 3B) The difference between the mean gestational age of EPs with the blob sign (41 days) and EP without the blob sign (45 days; ie, a combined group of the bagel and sign and a nonviable embryo) was statistically significant (P 5 .03). However, gestational age did not correlate with the success rate of management. The mean gestational age in the failure group was 43.9 6 10.7 days, whereas that in the success group was 44.4 6 13.5 days (P 5 .87).
Discussion
This study demonstrates that the morphologic type of tubal EP and the size of an inhomogeneous mass (in millimeters) do not seem to be independent predictors of success in women selected for nonsurgical management. 
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Higher serum hCG levels at 0 hours, however, were associated with management failure. This study was conducted in a tertiary referral early pregnancy assessment unit, and one must interpret the results with caution, as the study population was selfselected and may not be reflective of low-risk populations. Another limitation of our study was that the women who were eligible for nonsurgical management were not randomly allocated to either expectant or medical management. A randomized controlled study would be ideal for observing the natural history of tubal EP and the potential influence of the morphologic type on the outcome, as well as enabling a robust evaluation of methotrexate when compared to a "wait-and-watch" approach. Another limitation of our study was that the sample size was relatively small; however, when compared to other interventional studies evaluating the management of tubal EP, our sample size was comparable to published cohorts. 4, 16, 17 In our study, 50% of women were managed nonsurgically with success rates of 77% and 75% in the expectant and medical management groups, respectively. The success rate of nonsurgical management in the literature varies from 65% to 95%. This variation is largely due to different selection criteria used for patient eligibility in women who undergo nonsurgical management. 18, 19 Many previous studies have included nonvisualization of an intrauterine gestational sac as a diagnostic feature for EP. Studies using such inclusion criteria could well have misclassified an EP as a failing pregnancy of unknown location, which would have resolved spontaneously anyway. 20 To include such women for nonsurgical management has the potential to overinflate their published success rates for nonsurgical management of EPs. Importantly in our study, all of the tubal EPs were diagnosed by TVUS on the basis that there was positive visualization of an adnexal mass rather than the absence of an intrauterine gestational sac. 3 In our study, if there were no signs of an intrauterine or extrauterine pregnancy, we classified these women as have pregnancy of unknown location rather than EP.
Our findings are consistent with those reported by Frates et al, 4 who examined 231 cases, albeit retrospectively, and found no correlation between the EP morphologic type and subsequent tubal rupture. Similarly, Kirk et al 5 showed the EP morphologic type and size to be poor predictors of nonsurgical management success. In our study, we found an association between the EP mass size on US and hCG level at 0 hours. Larger-diameter EP masses were significantly associated with higher serum hCG levels at 0 hours and lower hCG ratios. This finding was similar to that of Guvendag Guven et al 21 ; however, in our study, the size of the EP mass did not seem to affect management success. Importantly, the size of the EP mass might have been influenced by the presence of blood in the pelvis, which can be associated with a blood clot surrounding the EP mass and has the potential to obscure the margins of the tubal EP mass and potentially result in an overestimation of the EP size on US.
Although the numbers were small in our study population, EP masses with diameters of greater than 30 mm in the expectant and medical management groups had success rates of 100% and 85%, respectively. Published protocols for the medical management of EP incorporate EP mass diameter cutoffs. The National Institute for Health and Care Excellence guidelines use an adnexal mass cutoff of 35 mm, below which nonsurgical management should be offered (in the context of clinical stability). 16 This cutoff is not different from other published studies, which were summarized in a metaanalysis by Mol et al 19 in 2008, in which success was associated with an EP mass of less than 30 to 40 mm. These studies, however, focused on medical management with methotrexate, with limited data available on expectant management. In our study, 27.8% of the tubal EP population had expectant management with a success rate of 77% regardless of the size of the EP mass, which therefore by itself was not a predictor of a successful outcome of nonsurgical management. This observation was also demonstrated in a recent randomized controlled trail comparing expectant management versus methotrexate treatment, 22 in which the investigators observed that the neither size nor the initial level of hCG correlated with success. The latter finding was in contrast to our study, in which a higher level of hCG at 0 hours was associated with failure of treatment in both the expectant and medical management groups. The association between a higher level of hCG at presentation and the failure rate of nonsurgical management has been demonstrated in many studies. 8, 11, 17 This association is especially so when the levels of serum hCG are higher than 1000 IU/L. Nevertheless, in our study, all levels of hCG at presentation were included, and a serum hCG cutoff of 1500 IU/L did not seem to affect the success of the management in either the expectant or medical management groups.
In conclusion, there is no significant correlation between the morphologic type and size of EP with the success rate of nonsurgical management. A likely successful outcome of nonsurgical management is related to lower levels of serum hCG at presentation.
